Medroxyprogesterone vs Dulaglutide: side-by-side comparison
Medroxyprogesterone (Progestin) and Dulaglutide (GLP-1 receptor agonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Medroxyprogesterone | Dulaglutide |
|---|---|---|
| Therapeutic class | Progestin | GLP-1 receptor agonist |
| CAS | 520-85-4 | 923950-08-7 |
| ATC | G03DA02 | A10BJ05 |
| Molecular weight | 344.49 g/mol | ~63 kDa |
| Brands with this active ingredient | 1 | 1 |
What they share
Medroxyprogesterone and Dulaglutide share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Medroxyprogesterone acts by a different mechanism than Dulaglutide, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Medroxyprogesterone: MPA binds progesterone receptors and produces strong progestational effects: thickening cervical mucus, inhibiting ovulation, thinning the endometrium and reducing hot flashes. Dulaglutide: Dulaglutide activates the GLP-1 receptor in pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon release from alpha cells.
Indications compared
Medroxyprogesterone: MPA is approved for amenorrhoea, abnormal uterine bleeding due to hormonal imbalance, prevention of endometrial hyperplasia in postmenopausal women receiving estrogen, and prevention of pregnancy (depot formulation). Dulaglutide: The medication is approved in adults with type 2 diabetes mellitus, as monotherapy when metformin is inappropriate or as add-on therapy to other antidiabetics, to improve glycaemic control.
Safety profile
Medroxyprogesterone: Common adverse effects of oral MPA include irregular bleeding, breast tenderness, mood changes, fluid retention and weight gain. Dulaglutide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting and abdominal pain, usually mild to moderate and decreasing over the first weeks of treatment.
Frequently asked questions
Is Medroxyprogesterone better than Dulaglutide? ▾
Medroxyprogesterone and Dulaglutide are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Medroxyprogesterone and Dulaglutide be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Medroxyprogesterone
Products with Dulaglutide
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.